Enduring Materials

Access slide decks and video via the links in the schedule below.

PDF = PDF of slides is available

= Presentation video is available

Program Schedule Wednesday, November 9, 2016
11:00 a.m. – 11:10 a.m.	Welcome and Introductions Daniel Chen, MD, PhD – Genentech
*Session I: New Agents in Development* Moderator: Adrian Bot, MD, PhD – Kite Pharma, Inc.
11:10 a.m. – 11:15 a.m.	Anti-Semaphorin4D VX15/2503 in Combination with Ipilimumab or Antibody to PD-1 or PD-L1 Elizabeth Evans, PhD - Vaccinex, Inc
11:15 a.m. – 11:20 a.m.	IMO-2125, An Investigational Intratumoral Toll-Like Receptor 9 Agonist, Modulates the Tumor Microenvironment to Enhance Anti-Tumor Immunity Mark Cornfeld, MD, MPH – Idera Pharmaceuticals
11:20 a.m. – 11:25 a.m.	Cobimetinib in Combination with Atezolizumab Edward Cha – Genentech
11:25 a.m. - 11:30 a.m.	Combination Strategy for Varlilumab, An Agonist Anti-CD27 Monoclonal Antibody Thomas Davis, MD – Celldex Therapeutics, Inc.
11:30 a.m.- 11:35 a.m.	Safety of the Natural Killer (NK) Cell-Targeted Anti-KIR Antibody, lirilumab (liri), in Combination with Nivolumab (nivo) or Ipilimumab (ipi) in Two Phase 1 Studies in Advanced Refractory Solid Tumors F. Stephen Hodi, MD – Dana-Farber Cancer Institute
11:35 a.m. - 11:40 a.m.	A CD122-Biased Agonist Increases CD8+T Cells and Natural Killer Cells in the Tumor Microenvironment; Making Cold Tumors Hot with NKTR-214 Adi Diab, MD – MD Anderson Cancer Center
11:40 a.m. – 11:45 a.m.	Activated Natural Killer (aNK) Cell Therapy Patrick Soon-Shiong, MD, FRCS, FACS – NantKwest
*Session II: Pre-Clinical New Agents in Development*
11:45 a.m. – 11:50 a.m.	CD3-EGFR Probody™ T Cell-Engaging Bispecific Induces Tumor Regressions and Substantially Increases Safety Window in Preclinical Studies Bryan A. Irving, PhD – Cytomx Therapeutics, Inc.
11:50 a.m. – 11:55 a.m.	PRS-343, a CD137 (4-1BB)/HER2 Bispecific Shane A. Olwill, PhD – Pieris Pharmaceuticals, Inc.
11:55 a.m. – 12:00 p.m.	pLADD: Personalized, Live, Attenuated Double-Deleted Listeria Monocytogenes Thomas W. Dubensky Jr., PhD – Aduro Biotech
12:00 p.m. – 12:05 p.m.	CA170: A Small Molecule Orally Available Checkpoint Inhibitor David Tuck, MD – Curis
12:05 p.m. – 12:10 p.m.	LAG-3Ig (IMP321) in Combination with Anti-PD-1 Therapy Frederic Triebel, MD, PhD – Prima Biomed Ltd
12:10 p.m. – 12:15 p.m.	Agent A - PD-1 DNR-41BB: Converting Tumor-Mediated PD-L1 Inhibition into CAR T-Cell Costimulation Prasad S. Adusumilli, MD, FACP, FCCP – Memorial Sloan Kettering Cancer Center
12:15 p.m. – 12:20 p.m.	The Immunoreceptor TIGIT Regulates Anti-Tumor Immunity Jane Grogan, PhD – Genentech
12:20 p.m. – 12:45 p.m.	Audience Question & Answer Adrian Bot, MD, PhD – Kite Pharma, Inc.
*Session III: Strategic Considerations of Combinations and Biomarkers in New Agent Development*
1:30 p.m. – 2:00 p.m.	Combinations & Biomarkers Charles G. Drake, MD, PhD – Columbia University Herbert Irving Comprehensive Cancer Center
2:00 p.m. – 3:25 p.m.	Extended Panel Discussion Co-Chairs: Andrian Bot, MD, PhD – Kite Pharma, Inc. Daniel Chen, MD, PhD – Genentech Roger Dansey, MD – Merck & Co., Inc. Ramy Ibrahim, MD – Parker Institute for Cancer Immunotherapy (formerly at AstraZeneca) Salil Patel – Bristol-Myers Squibb Faculty: Raj K. Puri, MD, PhD – U.S. Food & Drug Administration Marc Theoret, MD – U.S. Food & Drug Administration Charles G. Drake, MD, PhD – Columbia University Herbert Irving Comprehensive Cancer Center Gordon J. Freeman, PhD – Dana-Farber Cancer Institute
3:25 p.m. – 3:30 p.m.	Closing Remarks Roger Dansey, MD – Merck & Co., Inc.